Literature DB >> 20607226

The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.

Philip A Mudd1, Shari M Piaskowski, Patricia C Costa Neves, Richard Rudersdorf, Holly L Kolar, Christopher M Eernisse, Kim L Weisgrau, Marlon G Veloso de Santana, Nancy A Wilson, Myrna C Bonaldo, Ricardo Galler, Eva G Rakasz, David I Watkins.   

Abstract

The yellow fever vaccine 17D (YF17D) is one of the most effective vaccines. Its wide use and favorable safety profile make it a prime candidate for recombinant vaccines. It is believed that neutralizing antibodies account for a large measure of the protection afforded to YF17D-vaccinated individuals, however cytotoxic T lymphocyte (CTL) responses have been described in the setting of YF17D vaccination. YF17D is an ssRNA flavivirus that is translated as a full-length polyprotein, several domains of which pass into the lumen of the endoplasmic reticulum (ER). The processing and presentation machinery for MHC class I-restricted CTL responses favor cytoplasmic peptides that are transported into the ER by the transporter associated with antigen presentation proteins. In order to inform recombinant vaccine design, we sought to determine if YF17D-induced CTL responses preferentially targeted viral domains that remain within the cytoplasm. We performed whole YF17D proteome mapping of CTL responses in six Indian rhesus macaques vaccinated with YF17D using overlapping YF17D peptides. We found that the ER luminal E protein was the most immunogenic viral protein followed closely by the cytoplasmic NS3 and NS5 proteins. These results suggest that antigen processing and presentation in this model system is not preferentially affected by the subcellular location of the viral proteins that are the source of CTL epitopes. The data also suggest potential immunogenic regions of YF17D that could serve as the focus of recombinant T cell vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607226      PMCID: PMC3136048          DOI: 10.1007/s00251-010-0461-0

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  23 in total

1.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

Authors:  R G van Der Most; K Murali-Krishna; R Ahmed; J H Strauss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus.

Authors:  Myrna C Bonaldo; Richard C Garratt; Philippe S Caufour; Marcos S Freire; Mauricio M Rodrigues; Ruth S Nussenzweig; Ricardo Galler
Journal:  J Mol Biol       Date:  2002-01-25       Impact factor: 5.469

Review 3.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?

Authors:  J W Yewdell; L C Antón; J R Bennink
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

4.  Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.

Authors:  C S Hahn; J M Dalrymple; J H Strauss; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

6.  A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing.

Authors:  L A Knapp; E Lehmann; M S Piekarczyk; J A Urvater; D I Watkins
Journal:  Tissue Antigens       Date:  1997-12

7.  Genetic variability among yellow fever virus 17D substrains.

Authors:  R Galler; P R Post; C N Santos; I I Ferreira
Journal:  Vaccine       Date:  1998 May-Jun       Impact factor: 3.641

8.  Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition.

Authors:  John T Loffredo; John Sidney; Christina Wojewoda; Elizabeth Dodds; Matthew R Reynolds; Gnankang Napoé; Bianca R Mothé; David H O'Connor; Nancy A Wilson; David I Watkins; Alessandro Sette
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

Review 9.  Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.

Authors:  Ching-Juh Lai; Thomas P Monath
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

10.  Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.

Authors:  Cristina T Stoyanov; Silvia B Boscardin; Stephanie Deroubaix; Giovanna Barba-Spaeth; David Franco; Ruth S Nussenzweig; Michel Nussenzweig; Charles M Rice
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

View more
  10 in total

1.  Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection.

Authors:  Mauricio A Martins; Damien C Tully; Michael A Cruz; Karen A Power; Marlon G Veloso de Santana; David J Bean; Colin B Ogilvie; Rujuta Gadgil; Noemia S Lima; Diogo M Magnani; Keisuke Ejima; David B Allison; Michael Piatak; John D Altman; Christopher L Parks; Eva G Rakasz; Saverio Capuano; Ricardo Galler; Myrna C Bonaldo; Jeffrey D Lifson; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

Review 2.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

3.  Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications.

Authors:  Helen L Wu; Whitney C Weber; Christine Shriver-Munsch; Tonya Swanson; Mina Northrup; Heidi Price; Kimberly Armantrout; Mitchell Robertson-LeVay; Jason S Reed; Katherine B Bateman; Eisa Mahyari; Archana Thomas; Stephanie L Junell; Theodore R Hobbs; Lauren D Martin; Rhonda MacAllister; Benjamin N Bimber; Mark K Slifka; Alfred W Legasse; Cassandra Moats; Michael K Axthelm; Jeremy Smedley; Anne D Lewis; Lois Colgin; Gabrielle Meyers; Richard T Maziarz; Benjamin J Burwitz; Jeffrey J Stanton; Jonah B Sacha
Journal:  Xenotransplantation       Date:  2020-01-13       Impact factor: 3.907

4.  Reduction of CD4+ T cells in vivo does not affect virus load in macaque elite controllers.

Authors:  Philip A Mudd; Adam J Ericsen; Andrew A Price; Nancy A Wilson; Keith A Reimann; David I Watkins
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

5.  Characterisation of MHC haplotypes in a breeding colony of Indonesian cynomolgus macaques reveals a high level of diversity.

Authors:  Jane L Mitchell; Edward T Mee; Neil M Almond; Keith Cutler; Nicola J Rose
Journal:  Immunogenetics       Date:  2011-09-01       Impact factor: 2.846

6.  Phenotypic and Genetic Variability of Isolates of ZIKV-2016 in Brazil.

Authors:  Lidiane Menezes Souza Raphael; Iasmim Silva de Mello; Mariela Martínez Gómez; Ieda Pereira Ribeiro; Nathália Dias Furtado; Noemia Santana Lima; Alexandre Araújo Cunha Dos Santos; Déberli Ruiz Fernandes; Stephanie Oliveira Diaz da Cruz; Luana Santana Damasceno; Patrícia Brasil; Myrna Cristina Bonaldo
Journal:  Microorganisms       Date:  2022-04-21

Review 7.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

8.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

Review 9.  T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models.

Authors:  Alan M Watson; William B Klimstra
Journal:  Viruses       Date:  2017-04-11       Impact factor: 5.048

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.